Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development and implementation of clinical management guidelines

G J Bosl1

  • 1Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Oncology (Williston Park, N.Y.)
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

In vivo differentiation and genomic evolution in adult male germ cell tumors.

Genes, chromosomes & cancer·2007
Same author

Expression of ID genes in differentiated elements of human male germ cell tumors.

Diagnostic molecular pathology : the American journal of surgical pathology, part B·2002
Same author

A method for assessing house staff workload as a function of length of stay.

JAMA·2001
Same author

Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

ID gene expression varies with lineage during differentiation of pluripotential male germ cell tumor cell lines.

Cell and tissue research·2001
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Memorial Sloan-Kettering Cancer Center is developing a comprehensive disease management system. This prospective, longitudinal system integrates clinical outcomes, patient experience, and costs for improved cancer care.

Area of Science:

  • Oncology
  • Health Services Research
  • Health Informatics

Background:

  • Traditional cancer care often lacks integrated, longitudinal outcome measures.
  • There is a growing need for systems that incorporate patient-reported outcomes and cost-effectiveness.
  • Current disease management approaches may not fully capture the patient experience or economic impact.

Purpose of the Study:

  • To describe the development of a novel prospective, longitudinal disease management system at Memorial Sloan-Kettering Cancer Center.
  • To outline the system's key features, including integrated outcome measures and care coordination.
  • To highlight the system's potential to improve cancer care delivery by incorporating diverse outcome data.

Main Methods:

  • Development of a prospective, longitudinal disease management system.

Related Experiment Videos

  • Integration of traditional clinical outcomes (response, toxicity) with patient-reported outcomes and cost data.
  • Implementation of three core components: standards of care, information technology for data integration, and central coordination via disease management teams.

    • Main Results:

    • The system is designed to be prospective and longitudinal, capturing data over time.
    • It incorporates a comprehensive set of outcome measures, extending beyond clinical response and toxicity.
    • Key features include defined standards of care, robust information technology infrastructure, and dedicated disease management teams.

    Conclusions:

    • The developed disease management system offers a holistic approach to cancer care.
    • Integration of clinical, patient-reported, and cost outcomes is central to the system's design.
    • The system's framework, emphasizing standards of care, IT integration, and team coordination, is poised to enhance disease management strategies.